A new study from Colombia’s Universidad de Antioquia, published in the peer reviewed journal Medical Cannabis and Cannabinoids, highlights CBD-rich oil as a treatment option for neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD).

CBD oil.
In a two-year prospective study, researchers observed that a majority of patients experienced significant improvements in symptoms and a reduction in caregiver distress. This open-label study reveals that CBD oil could provide a safer, effective alternative for managing challenging AD symptoms, particularly for those with disease onset after age 65.
The study, titled Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease with a Cannabis-Based Magistral Formulation: An Open-Label Prospective Cohort Study, was conducted between July 2020 and July 2023 with researchers from Universidad de Antioquia and two research hospitals in Colombia. It aimed to evaluate the effectiveness and safety of CBD-rich oil in treating neuropsychiatric symptoms for Alzheimer’s patients, a common issue impacting both patients and their caregivers.
Continue reading